Role of Neoadjuvant Chemotherapy (NACT) Followed by Surgical Cytoreduction in Advanced Epithelial Ovarian Cancer

新辅助化疗(NACT)联合手术减瘤术在晚期上皮性卵巢癌治疗中的作用

阅读:1

Abstract

OBJECTIVES: To study the role of neoadjuvant chemotherapy (NACT) followed by surgical cytoreduction in the management of advanced epithelial ovarian cancers. METHODS: A prospective hospital based study of patients with advanced epithelial ovarian cancers (stage III and IV) was conducted at Gujarat Cancer & Research Institute, Ahmedabad during August 2008 to August 2010. Total 50 patients were treated with NACT followed by surgical cytoreduction and followed up till August 2010. Response to NACT, optimal cytoreduction rate and overall response rate were analyzed. RESULTS: There were 43 patients (86%) with stage III disease and 7 (14%) with stage IV disease. All patients were given NACT and after NACT, complete response occurred in 17 patients (34%), 27 (54%) had partial response. Optimal surgical cytoreduction could be achieved in 36(72%) of the patients. The median follow up was 19 months. CONCLUSIONS: NACT followed by surgical cytoreduction is a promising treatment strategy for the management of advanced epithelial ovarian cancers.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。